Enhanced anti-cancer activity of andrographis with oligomeric proanthocyanidins through activation of metabolic and ferroptosis pathways in colorectal cancer.
Andrographis
/ metabolism
Animals
Antioxidants
/ pharmacology
Apoptosis
/ drug effects
Carcinogenesis
/ drug effects
Cell Line, Tumor
Colorectal Neoplasms
/ drug therapy
Diterpenes
/ pharmacology
Drug Therapy, Combination
/ methods
Ferroptosis
/ drug effects
Humans
Male
Mice
Mice, Nude
Organoids
/ drug effects
Plant Extracts
/ pharmacology
Proanthocyanidins
/ metabolism
Xenograft Model Antitumor Assays
/ methods
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
06 04 2021
06 04 2021
Historique:
received:
28
09
2020
accepted:
22
03
2021
entrez:
7
4
2021
pubmed:
8
4
2021
medline:
9
11
2021
Statut:
epublish
Résumé
The high degree of morbidity and mortality in colorectal cancer (CRC) patients is largely due to the development of chemoresistance against conventional chemotherapeutic drugs. In view of the accumulating evidence that various dietary botanicals offer a safe, inexpensive and multi-targeted treatment option, herein, we hypothesized that a combination of Andrographis paniculata and Oligomeric Proanthocyanidins (OPCs) might interact together with regard to anti-tumorigenic activity in CRC. As a result, we demonstrated the enhanced anti-cancer activity between these two botanical extracts in terms of their ability to inhibit cancer cell growth, suppress colony formation and induce apoptosis. Furthermore, we validated these findings in subcutaneous xenograft model and in patient derived primary epithelial 3D organoids. Transcriptomic profiling identified involvement of metabolic pathways and ferroptosis-associated genes, including HMOX1, GCLC and GCLM, that may be responsible for the increased anti-tumorigenic activity by the two compounds. Collectively, our study provides novel evidence in support of the combinatorial use of andrographis and OPCs as a potential therapeutic option, perhaps as an adjunctive treatment to classical drugs, in patients with colorectal cancer.
Identifiants
pubmed: 33824419
doi: 10.1038/s41598-021-87283-y
pii: 10.1038/s41598-021-87283-y
pmc: PMC8024269
doi:
Substances chimiques
Antioxidants
0
Diterpenes
0
Plant Extracts
0
Proanthocyanidins
0
andrographolide
410105JHGR
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
7548Références
J Nat Prod. 2016 Mar 25;79(3):629-61
pubmed: 26852623
Asian J Androl. 2018 Mar-Apr;20(2):200-204
pubmed: 28869219
Cancer Prev Res (Phila). 2015 May;8(5):431-43
pubmed: 25712055
Nature. 2012 Jun 28;486(7404):537-40
pubmed: 22722843
Carcinogenesis. 2012 Dec;33(12):2441-9
pubmed: 22983985
Cancer Res. 2010 Jan 15;70(2):440-6
pubmed: 20068163
J Clin Pharm Ther. 2004 Feb;29(1):37-45
pubmed: 14748896
Carcinogenesis. 2013 Aug;34(8):1843-51
pubmed: 23615401
Biochem Pharmacol. 2014 Sep 1;91(1):40-50
pubmed: 24998495
Carcinogenesis. 2019 May 14;40(3):412-421
pubmed: 30596962
Proc Am Thorac Soc. 2005;2(4):282-9; discussion 290-1
pubmed: 16267349
Proc Natl Acad Sci U S A. 2004 Mar 23;101(12):4164-9
pubmed: 15016911
J Theor Biol. 2014 Aug 21;355:10-20
pubmed: 24681298
Oncol Lett. 2017 Oct;14(4):4305-4310
pubmed: 28943944
In Vitro Cell Dev Biol Anim. 1996 Jun;32(6):315-7
pubmed: 8842743
Nat Rev Clin Oncol. 2017 Apr;14(4):235-246
pubmed: 27922044
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Annu Rev Pharmacol Toxicol. 2016;56:85-102
pubmed: 26514196
Cell Oncol (Dordr). 2017 Dec;40(6):563-578
pubmed: 28929377
BMC Bioinformatics. 2010 Jul 02;11:367
pubmed: 20598126
Cancer Lett. 2018 Apr 28;420:129-145
pubmed: 29408515
Mol Cancer Res. 2013 Dec;11(12):1554-63
pubmed: 24140838
Pharm Biol. 2016 Nov;54(11):2629-2635
pubmed: 27159496
Carcinogenesis. 2018 May 28;39(6):767-777
pubmed: 29684110
Nutr Cancer. 2010;62(7):919-30
pubmed: 20924967
Sci Rep. 2018 Feb 20;8(1):3335
pubmed: 29463813
Cell. 2015 May 7;161(4):933-45
pubmed: 25957691
FASEB J. 2008 Mar;22(3):659-61
pubmed: 17942826
Toxicol Lett. 2013 Sep 12;222(1):23-35
pubmed: 23845849
Sci Rep. 2018 Sep 14;8(1):13869
pubmed: 30218018
Nat Med. 2019 May;25(5):838-849
pubmed: 31011202
Toxicol Sci. 2014 May;139(1):108-20
pubmed: 24563380
Sci Rep. 2018 May 21;8(1):7924
pubmed: 29784906
Oncotarget. 2015 Sep 15;6(27):24393-403
pubmed: 26405158
Oncogene. 2018 Feb 22;37(8):1107-1118
pubmed: 29155422
Mol Nutr Food Res. 2008 Sep;52(9):1010-30
pubmed: 18384098
J Agric Food Chem. 2018 May 23;66(20):5139-5148
pubmed: 29672044
Cell. 2017 Oct 5;171(2):273-285
pubmed: 28985560
Biochem Pharmacol. 2016 Dec 1;121:8-17
pubmed: 27693317
Arch Pharm Res. 2018 Jan;41(1):1-13
pubmed: 29230689
Cancer Manag Res. 2018 May 10;10:1079-1088
pubmed: 29785137
Carcinogenesis. 2020 Oct 15;41(10):1385-1394
pubmed: 32835374
J Clin Oncol. 2000 Jan;18(1):136-47
pubmed: 10623704
Tumour Biol. 2017 May;39(5):1010428317705330
pubmed: 28513299
Elife. 2013 Jun 25;2:e00747
pubmed: 23805382
PLoS One. 2013;8(2):e57709
pubmed: 23460897
Biochem Pharmacol. 2008 Feb 15;75(4):787-809
pubmed: 17900536